Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL2399914 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1614041 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Dodecane SCHEMBL1747351 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1190938 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL9107982 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL11904142 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL276236 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1680974 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Hexadecane SCHEMBL3291441 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL18725336 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217069-B2 | Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100112090-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100112090-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | NR5A1, SHBG, GNRHR | ALDH1A1 3357/4885LMNA 4373/4885HSD17B10 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.